AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22423956 — intervention group
Group type: EXPERIMENTAL
Intervention: Gasless technique under epidural anesthesia (Group EG)
Number of subjects: 57
Study 20074380 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary electrophoresis
Number of subjects: 0
Study 20074380 — intervention group
Group type: COMPARATOR
Intervention: Agarose gel electrophoresis
Number of subjects: 0
Study 17663615 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping and communication-enhancing intervention (CCI)
Number of subjects: 353
Study 17663615 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive counseling (SC)
Number of subjects: 353
Study 17663615 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 353
Study 16026123 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib and rofecoxib
Number of subjects: 0
Study 16026123 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant drugs
Number of subjects: 0
Study 11802045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (0.5 mg/kg bolus intravenously, followed by 3 mg/kg continuous infusion over 24 hours, and 3 to 5 mg/kg per day at home)
Number of subjects: 102
Study 11802045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen combined with paracetamol-codeine
Number of subjects: 102
Study 11802045 — intervention group
Group type: COMPARATOR
Intervention: Normal saline and oxycodone (control group)
Number of subjects: 102
Study 11802045 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study group
Number of subjects: 102
Study 10073786 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 67
Study 10073786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 7494612 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cellulose membranes
Number of subjects: 0
Study 7494612 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose triacetate membranes
Number of subjects: 0
Study 7494612 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 2269542 — intervention group
Group type: EXPERIMENTAL
Intervention: DPI 201‐106 (20 mg)
Number of subjects: 20
Study 2269542 — intervention group
Group type: EXPERIMENTAL
Intervention: DPI 201‐106 (40 mg)
Number of subjects: 20
Study 2269542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6308702 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (20 mg i.v.)
Number of subjects: 12
Study 6308702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6308702 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (20 micrograms/kg/hr) for 40 min by i.v. infusion
Number of subjects: 12
Study 6308702 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin rise
Number of subjects: 12
Study 31550197 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-Based Counseling Program (CARE+ Kenya)
Number of subjects: 236
Study 31550197 — intervention group
Group type: COMPARATOR
Intervention: Risk-assessment only control
Number of subjects: 236
Study 28799413 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment for Depression (BATD-HIV)
Number of subjects: 10
Study 26857924 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard concomitant administration of bevacizumab with chemotherapy (mFOLFOX/OXXEL regimen)
Number of subjects: 230
Study 26857924 — intervention group
Group type: COMPARATOR
Intervention: Experimental sequential bevacizumab given 4 days before chemotherapy
Number of subjects: 230
Study 24556231 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC)
Number of subjects: 48
Study 24556231 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 23218935 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine .5% with ketorolac .6 mg/hour
Number of subjects: 60
Study 23218935 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine .5% with hydromorphone .04 mg/hour
Number of subjects: 60
Study 23218935 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine .5% (active control)
Number of subjects: 60
Study 20824678 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg saxagliptin once daily for 18 weeks
Number of subjects: 801
Study 20824678 — intervention group
Group type: COMPARATOR
Intervention: 100 mg sitagliptin once daily for 18 weeks
Number of subjects: 801
Study 20824678 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg saxagliptin plus metformin
Number of subjects: 801
Study 20824678 — intervention group
Group type: COMPARATOR
Intervention: 100 mg sitagliptin plus metformin
Number of subjects: 801
Study 20824678 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 801
Study 18410225 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium citrate 1000 mg/day + vitamin D(2) 1000 IU
Number of subjects: 302
Study 18410225 — intervention group
Group type: COMPARATOR
Intervention: Calcium citrate 1000 mg/day + placebo
Number of subjects: 302
Study 15763608 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam 1 mg
Number of subjects: 18
Study 15763608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12724503 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (N=70)
Number of subjects: 137
Study 12724503 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N=67)
Number of subjects: 137
Study 10556125 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NPPV)
Number of subjects: 56
Study 10556125 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 56
Study 10556125 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV in patients with COPD
Number of subjects: 56
Study 8732628 — intervention group
Group type: COMPARATOR
Intervention: Leukocyte count
Number of subjects: 154
Study 8732628 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein (CRP)
Number of subjects: 154
Study 8732628 — intervention group
Group type: COMPARATOR
Intervention: Fibrinogen
Number of subjects: 154
Study 8732628 — intervention group
Group type: COMPARATOR
Intervention: Leukocyte count, fibrinogen, and CRP
Number of subjects: 154
Study 1930344 — intervention group
Group type: EXPERIMENTAL
Intervention: Kava extract WS 1490 (Laitan) 3 x 100 mg/day
Number of subjects: 58
Study 1930344 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 58
Study 7149056 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous haloperidol
Number of subjects: 0
Study 7149056 — intervention group
Group type: COMPARATOR
Intervention: Oral haloperidol
Number of subjects: 0
Study 31776310 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail-based intervention using the TAKE10! Program (monthly mail with self-check sheets and feedback for 5 months)
Number of subjects: 143
Study 31776310 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 143
Study 28013054 — intervention group
Group type: EXPERIMENTAL
Intervention: CCT
Number of subjects: 114
Study 28013054 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT
Number of subjects: 114
Study 27102290 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 110
Study 27102290 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 110
Study 24524399 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 544
Study 24524399 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 544
Study 22081481 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg daily
Number of subjects: 568
Study 22081481 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 568
Study 19084393 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine and oxaliplatin (CAPOX)
Number of subjects: 91
Study 17403312 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (60 ml/min)
Number of subjects: 160
Study 15188109 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg of tranexamic acid
Number of subjects: 50
Study 15188109 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 50
Study 11384785 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive clinical trials (ACTs)
Number of subjects: 0
Study 11384785 — intervention group
Group type: COMPARATOR
Intervention: Randomized clinical trials (RCTs)
Number of subjects: 0
Study 9705731 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-down encoding with explicit instructions to attend to the relevant feature
Number of subjects: 0
Study 9705731 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal attention conditions
Number of subjects: 0
Study 9705731 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit instructions or other factors
Number of subjects: 0
Study 8198894 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual measurement of QT interval with greater amplifier gain
Number of subjects: 8
Study 8198894 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual measurement of QT interval at slower paper speeds
Number of subjects: 8
Study 8198894 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual measurement of QT interval by different cardiologists
Number of subjects: 8
Study 2642497 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1 (900 micrograms/m2 subcutaneously twice weekly for eight doses)
Number of subjects: 90
Study 2642497 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same schedule as thymosin alpha 1)
Number of subjects: 90
Study 978238 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensate for arm deflection instruction
Number of subjects: 23
Study 978238 — intervention group
Group type: EXPERIMENTAL
Intervention: Do not intervene voluntarily instruction
Number of subjects: 23
Study 978238 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased force disturbance
Number of subjects: 23
Study 978238 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased force disturbance
Number of subjects: 23
Study 978238 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetric disturbances
Number of subjects: 23
Study 978238 — intervention group
Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 23
Study 31532035 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care nursing programme (A)
Number of subjects: 378
Study 31532035 — intervention group
Group type: COMPARATOR
Intervention: Standard care (B)
Number of subjects: 378
Study 31568997 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated home-visitation program delivered by community health workers including psychosocial stimulation and health promotion during bi-weekly home visits over one year.
Number of subjects: 449
Study 31568997 — intervention group
Group type: COMPARATOR
Intervention: Control group received no home visits.
Number of subjects: 449
Study 28577682 — intervention group
Group type: EXPERIMENTAL
Intervention: CR+DHI (Digital Health Intervention)
Number of subjects: 80
Study 28577682 — intervention group
Group type: COMPARATOR
Intervention: Standard CR (Control)
Number of subjects: 80
Study 25056665 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic intervention (communication of sleep test results and importance of CPAP adherence)
Number of subjects: 321
Study 25056665 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 321
Study 22915172 — intervention group
Group type: EXPERIMENTAL
Intervention: Tethered swimming (SW)
Number of subjects: 12
Study 22915172 — intervention group
Group type: COMPARATOR
Intervention: Cycling (CY)
Number of subjects: 12
Study 22915172 — intervention group
Group type: COMPARATOR
Intervention: Arm cranking (AC)
Number of subjects: 12
Study 22915172 — intervention group
Group type: COMPARATOR
Intervention: Running (RU)
Number of subjects: 12
Study 21302042 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of enteric-coated pantoprazole
Number of subjects: 20
Study 19319218 — intervention group
Group type: EXPERIMENTAL
Intervention: Family psychoeducation and support group (n = 34)
Number of subjects: 68
Study 19319218 — intervention group
Group type: COMPARATOR
Intervention: Routine care group (n = 34)
Number of subjects: 68
Study 16186075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 17beta‐estradiol (Aerodiol) administration
Number of subjects: 18
Study 16186075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12519853 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin acetate 3.6 mg by sc injection every 4 weeks for 12 weeks (Group 1)
Number of subjects: 70
Study 12519853 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin plus transdermal testosterone (Androderm 5 mg topically daily) (Group 2)
Number of subjects: 70
Study 12519853 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin plus testosterone plus an aromatase inhibitor (anastrozole 1 mg orally daily) (Group 3)
Number of subjects: 70
Study 10992176 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg daily)
Number of subjects: 100
Study 10992176 — intervention group
Group type: COMPARATOR
Intervention: Continuous combined hormone replacement therapy (2 mg 17beta-estradiol plus 1 mg norethindrone acetate daily)
Number of subjects: 100
Study 8773422 — intervention group
Group type: EXPERIMENTAL
Intervention: Advantage 24 applied at 15-30 minutes before intercourse
Number of subjects: 139
Study 8773422 — intervention group
Group type: COMPARATOR
Intervention: Conceptrol applied at 15-30 minutes before intercourse
Number of subjects: 139
Study 8773422 — intervention group
Group type: EXPERIMENTAL
Intervention: Advantage 24 applied at 12 hours before intercourse
Number of subjects: 139
Study 8773422 — intervention group
Group type: EXPERIMENTAL
Intervention: Advantage 24 applied at 24 hours before intercourse
Number of subjects: 139
Study 1475038 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 0.25 mg rolipram/day
Number of subjects: 58
Study 1475038 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 0.50 mg rolipram/day
Number of subjects: 58
Study 1475038 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 1.00 mg rolipram/day
Number of subjects: 58
Study 6427826 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes with varying nicotine and tar yields
Number of subjects: 25
Study 6427826 — intervention group
Group type: COMPARATOR
Intervention: Non-smoking control condition
Number of subjects: 25
Study 6427826 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher nicotine yielding cigarettes
Number of subjects: 25
Study 30839067 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based telehealth (HBT)
Number of subjects: 180
Study 30839067 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home-in-person (IHIP)
Number of subjects: 180
Study 30839067 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based telehealth (OBT)
Number of subjects: 180
Study 28856388 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol injections
Number of subjects: 48
Study 28856388 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (placebo)
Number of subjects: 48
Study 26598571 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel treatment schedules (specific dosage and duration not mentioned)
Number of subjects: 11964
Study 24599454 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic visual stimuli presented in one visual hemifield
Number of subjects: 0
Study 24599454 — intervention group
Group type: COMPARATOR
Intervention: Arhythmic visual stimuli presented in the other visual hemifield
Number of subjects: 0
Study 24599454 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger alpha entrainment
Number of subjects: 0
Study 22993930 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin plus standard antibacterial therapy (3rd generation cephalosporins)
Number of subjects: 25
Study 22993930 — intervention group
Group type: COMPARATOR
Intervention: Standard antibacterial therapy (3rd generation cephalosporins)
Number of subjects: 25
Study 19915829 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg (nighttime dosing)
Number of subjects: 14
Study 19915829 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg (daytime dosing)
Number of subjects: 14
Study 19915829 — intervention group
Group type: COMPARATOR
Intervention: Comparison of nighttime vs daytime dosing
Number of subjects: 14
Study 19915829 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety assessment
Number of subjects: 14
Study 18992161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin
Number of subjects: 535
Study 18992161 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 535
Study 18992161 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity change (continuous)
Number of subjects: 535
Study 12775860 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) 250 micro g administered twice daily
Number of subjects: 26
Study 12775860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 10684846 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectacles
Number of subjects: 289
Study 10684846 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group: children with strabismus)
Number of subjects: 289
Study 9085945 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg bolus followed by an infusion of 5 mg/h for 24 h
Number of subjects: 0
Study 9085945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8448098 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% injected at L2-3 interspace
Number of subjects: 20
Study 8448098 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% injected at L4-5 interspace
Number of subjects: 20
Study 3536377 — intervention group
Group type: COMPARATOR
Intervention: 50 mg methadone
Number of subjects: 5
Study 3536377 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg methadone
Number of subjects: 5
Study 3536377 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg methadone
Number of subjects: 5
Study 3536377 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg methadone
Number of subjects: 5
Study 29107078 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical-grade honey (MGH)
Number of subjects: 86
Study 29107078 — intervention group
Group type: COMPARATOR
Intervention: Mupirocin 2%
Number of subjects: 86
Study 29231565 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection of human placenta tissue fluid combined with oral administration of metformin hydrochloride enteric-coated tablets
Number of subjects: 60
Study 29231565 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of metformin hydrochloride enteric-coated tablets
Number of subjects: 60
Study 24503176 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (200mg per day)
Number of subjects: 92
Study 24503176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 22615527 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mug
Number of subjects: 17
Study 22615527 — intervention group
Group type: COMPARATOR
Intervention: Oxitropium 0.2 mg x 3 mg
Number of subjects: 17
Study 20636724 — intervention group
Group type: EXPERIMENTAL
Intervention: Straumann Bone Ceramic (SBC)
Number of subjects: 27
Study 20636724 — intervention group
Group type: COMPARATOR
Intervention: Bio-Oss deproteinized bovine bone mineral (DBBM)
Number of subjects: 27
Study 18227298 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute presurgery hypnosis session
Number of subjects: 90
Study 18227298 — intervention group
Group type: COMPARATOR
Intervention: 15-minute presurgery attention control session
Number of subjects: 90
Study 15830958 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for TOS
Number of subjects: 280
Study 15830958 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for TOS (in second group)
Number of subjects: 280
Study 12606909 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track cardiac anesthesia (FTCA)
Number of subjects: 120
Study 12606909 — intervention group
Group type: COMPARATOR
Intervention: Conventional anesthetic
Number of subjects: 120
Study 10354167 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA‐PDT with white light applied three times within 10 days (W3)
Number of subjects: 30
Study 10354167 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA‐PDT with white light applied once (W1)
Number of subjects: 30
Study 10354167 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA‐PDT with red light applied three times within 10 days (R3)
Number of subjects: 30
Study 10354167 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA‐PDT with blue light applied three times within 10 days (B3)
Number of subjects: 30
Study 10354167 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy applied up to four times within 2 months (CRYO)
Number of subjects: 30
Study 10999066 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg i.v. prior to chemotherapy followed by two further doses of 8 mg i.v. over the first 24 hours, then 8 mg b.d. orally for the next 5 days
Number of subjects: 93
Study 10999066 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 20 mg i.v. prior to chemotherapy followed by 2 i.v. doses of 10 mg each, 4 hours apart, then 20 mg orally for the next 5 days
Number of subjects: 93
Study 1649672 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin (NOVO)
Number of subjects: 16
Study 1649672 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocomponent porcine insulin
Number of subjects: 16
Study 6871053 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl plus i.v. anaesthesia
Number of subjects: 45
Study 6871053 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal plus i.v. anaesthesia
Number of subjects: 45
Study 6871053 — intervention group
Group type: COMPARATOR
Intervention: i.v. anaesthesia alone
Number of subjects: 45
Study 30292891 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive urine LAM testing (n=1257)
Number of subjects: 2528
Study 30292891 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine diagnostics plus adjunctive urine LAM testing (n=1257)
Number of subjects: 2528
Study 30292891 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher LAM grade (grades 4 and 5)
Number of subjects: 2528
Study 30292891 — intervention group
Group type: COMPARATOR
Intervention: Routine diagnostics (n=1271)
Number of subjects: 2528